Drug Profile
Research programme: acne therapeutics - sanofi-aventis
Alternative Names: DL 6063Latest Information Update: 18 Mar 2009
Price :
$50
*
At a glance
- Originator sanofi-aventis
- Class
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Acne
Most Recent Events
- 18 Mar 2009 Discontinued - Preclinical for Acne in France (Topical)
- 27 Feb 2007 Preclinical trials in Acne in France (Topical)